Hu Kui, Wan Yun, Lee Fu-Tsuen, Chen Jinmiao, Wang Hao, Qu Haonan, Chen Tao, Lu Wang, Jiang Zhenwei, Gao Lufang, Ji Xiaojuan, Sun Liqun, Xiang Daokang
Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China.
Department of Endocrinology, Guizhou Provincial People's Hospital, Guiyang, China.
Front Genet. 2022 Apr 25;13:857095. doi: 10.3389/fgene.2022.857095. eCollection 2022.
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder that canonically affects the ocular, skeletal, and cardiovascular system, in which aortic tear and rupture is the leading cause of death for MFS patients. Genetically, MFS is primarily associated with fibrillin-1 (FBN1) pathogenic variants. However, the disease-causing variant in approximately 10% of patients cannot be identified, partly due to some cryptic mutations that may be missed using routine exonic sequencing, such as non-coding intronic variants that affects the RNA splicing process. We present a 32-year female with typical MFS systemic presentation that reached to a clinical diagnosis according to the revised Ghent nosology. We performed whole-exome sequencing (WES) but the report failed to identify known causal variants when analyzing the exonic sequence. However, further investigation on the exon/intron boundaries of the WES report revealed a candidate intronic variant of the fibrillin 1 (FBN1) gene (c.248-3 C>G) that predicted to affect the RNA splicing process. We conducted minigene splicing analyses and demonstrated that the c.248-3 C>G variant abolished the canonical splicing site of intron 3, leading to activation of two cryptic splicing sites and causing insertion (c.248-1_248-2insAG and c.248-1_248-282ins). Our study not only characterizes an intronic variant to the mutational spectrum of the FBN1 gene in MFS and its aberrant effect on splicing, but highlights the importance to not neglect the exon/intron boundaries when reporting and assessing WES results. We point out the need of conducting functional analysis to verify the pathogenicity of intronic mutation, and the opportunity to re-consider the standard diagnostic approaches in cases of clinically diagnosed MFS with normal or variant of unknown significance genetic results.
马凡综合征(MFS)是一种常染色体显性遗传性结缔组织疾病,典型地影响眼、骨骼和心血管系统,其中主动脉撕裂和破裂是MFS患者的主要死因。从遗传学角度来看,MFS主要与原纤蛋白-1(FBN1)的致病变异相关。然而,约10%的患者中致病变异无法被识别,部分原因是一些隐匿性突变可能会被常规外显子测序遗漏,比如影响RNA剪接过程的非编码内含子变异。我们报告了一名32岁女性,她具有典型的MFS全身表现,根据修订后的根特分类法达成临床诊断。我们进行了全外显子组测序(WES),但分析外显子序列时报告未能识别出已知的致病变异。然而,对WES报告中外显子/内含子边界的进一步研究揭示了原纤蛋白1(FBN1)基因的一个候选内含子变异(c.248-3 C>G),该变异预计会影响RNA剪接过程。我们进行了小基因剪接分析,并证明c.248-3 C>G变异消除了内含子3的典型剪接位点,导致两个隐匿性剪接位点激活,并造成插入(c.248-1_248-2insAG和c.248-1_248-282ins)。我们的研究不仅将一个内含子变异特征化为MFS中FBN1基因的突变谱及其对剪接的异常影响,还强调了在报告和评估WES结果时不可忽视外显子/内含子边界的重要性。我们指出需要进行功能分析以验证内含子突变的致病性,以及在临床诊断为MFS但基因结果正常或意义不明变异的情况下重新考虑标准诊断方法的机会。